Clinical study to know the efficacy of Dhartripanaka in vomitting in pregnancy

A RANDOMIZED OPEN LABELLED CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY OF DHATRIPANAKA IN GARBINI CHARDI W.S.R EMESIS GRAVIDARUM

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/039970

Enrollment

Registered

2022-02-02

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K929- Disease of digestive system, unspecified Health Condition 2: K319- Disease of stomach and duodenum, unspecified Health Condition 3: O210- Mild hyperemesis gravidarum

Interventions

Intervention1: Dhatripanaka: Dhatripanaka 50 ml QID Time of Admistration - before food Duration of Treatment -15 days Control Intervention1: Tablet Doxinate: Tablet Doxinate 10 mg 1tablet BD Time of

Eligibility

Inclusion criteria

Inclusion criteria: a) Subjects having confirm diagnosis of pregnancy. b) Subjects presenting the classical symptoms of Garbhini chardi. c) Subjects presenting with symptoms of Emesis Gravidarum. d) Subjects diagnosed as Garbhini chardi in all trimester pregnancy. e) Primigravida and multigravida.

Exclusion criteria

Exclusion criteria: a)Subjects with Hyper emesis gravidarum. b) Vomiting caused due Intestinal infestation, Urinary tract infection. c) Vomiting caused due to Peptic ulcer, Appendicitis. d) Vomiting caused due Red degeneration fibroid, Twisted Ovarian tumour. e) COVID-19 Positive

Design outcomes

Primary

Measure	Time frame
Dhatripanaka is effective in reducing nausea and vomitting Timepoint: On 8thday On 15th day On 30th day	—

Secondary

Measure	Time frame
tablet Doxinate was proved to be effective in Garbhini Chardi w.s.r Emesis Gravidarum, which will be assessed by the scales with PQUE scaleTimepoint: 8thday, 15th day, 30th day	—

Countries

India

Contacts

Public ContactDr Dharmista Patel

Sri Sri college of Ayurvedic science and Research

dr.rachanabhat@gmail.com9535744077

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026